Pearl Announces Global Collaboration with vVARDIS to Transform Early Detection and Proactive Treatment of Early Dental Decay
Pearl's AI solutions enable dental providers to accurately detect conditions such as decay or cavities at their earliest stages, ensuring a proactive approach to oral health. Beyond early condition detection, Pearl also builds patient trust by enhancing their understanding of dental imagery, leading to higher patient acceptance and more informed treatment decisions.
vVARDIS' Curodont™ offers a drill-free brush-on solution to aid hydroxyapatite formation throughout the early decay, helping patients to preserve the natural tooth structure and helping to avoid invasive and costly fillings. Up to 80% of all patients have tooth decay in early stages 1. Curodont™ gives dental professionals the opportunity to treat these patients with a simple and fast topical application during the same visit it's detected, without the need for a new appointment.
'At Pearl, we are dedicated to enhancing and standardizing dental diagnostics by leveraging AI to simplify radiograph interpretation and improve patient communication,' said Ophir Tanz, CEO and founder of Pearl. 'Our collaboration with vVARDIS enables a comprehensive, internationally scalable approach to early intervention against dental decay, giving patients more options for an effective and proactive path to improved oral health.'
'Partnering with Pearl is a natural progression in our mission to provide innovative solutions for early stage dental decay,' said Jeremy Thomas, President, vVARDIS North America. 'This collaboration equips global dental professionals with modern tools to detect conditions sooner and provides a proven, non-invasive solution to help restore enamel health.'
'As both dentists and entrepreneurs, we are thrilled to finally have and offer a groundbreaking approach to treating early decay,' said Drs. Haley and Goly Abivardi, DMDs, Founders and Co-CEOs of vVARDIS. '34 million school hours are lost each year due to emergency dental care 2 and $45 billion in lost productivity annually from untreated oral disease in the United States 3,4. Dental professionals have been waiting for decades for a drill-free treatment that addresses the sub-clinical signs of caries in the same visit. With its seamless integration into existing workflows, we believe that Curodont™ has the potential to rapidly become the new standard of care for the treatment of early caries, broadening the scope of services offered and empowering dentists and hygienists to lead the way in the management of early caries, ultimately enhancing patient care.'
About Pearl
Pearl is an AI-driven company committed to enhancing patient care in dentistry. Founded in 2019 by a team with decades of experience developing successful, enterprise-grade computer vision solutions, Pearl introduced the first-ever FDA-cleared AI capable of reading and instantly identifying diseases in dental x-rays. With regulatory clearance in 120 countries, Pearl's AI assists dentists in making precise clinical decisions and effectively communicating with patients, thereby transforming the dental care experience worldwide. As dentistry's global AI leader, Pearl is committed to the ongoing innovation of robust, accessible AI tools that improve patient health outcomes and build greater trust in dental medicine. To request a demo, please visit hellopearl.com/getdemo
About vVARDIS
vVARDIS is an innovative Swiss healthcare company located in Zug, Switzerland that offers groundbreaking biomimetic, non-invasive solutions for dental professionals under the Curodont™ brand. Founded by Swiss dentists, innovators and awarded entrepreneurs, Dr. Haley Abivardi, DMD and Dr. Goly Abivardi, DMD, vVARDIS is the result of more than 25 years of research, paired with the commitment of its founders to make an impact on people's lives, including the underserved.
vVARDIS' mission is to expand access to novel approaches to the standard of care in dentistry with the purpose of improving oral health – the foundation for overall health. vVARDIS science is backed by 25 years of research and more than 200 scientific publications, including meta-analysis, peer-reviewed clinical studies and a long-term peer-reviewed real-world evidence study, with hundreds of thousands of patients being treated successfully.
For more information, visit vVARDIS at www.vVARDIS.com and www.linkedin.com/company/vvardis.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
23 minutes ago
- Business Wire
BiVACOR Total Artificial Heart Accepted into FDA's Total Product Life Cycle (TAP) Program
HUNTINGTON BEACH, Calif.--(BUSINESS WIRE)--BiVACOR, Inc., a clinical-stage medical device company developing the world's first titanium Total Artificial Heart (TAH), today announced that its TAH System has been accepted into the U.S. Food and Drug Administration's (FDA) prestigious Total Product Life Cycle (TPLC) Advisory Program, also known as the TAP program. This milestone further solidifies BiVACOR's collaboration with the FDA following the TAH's earlier recognition this year as a Breakthrough Device. This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology. The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with urgency and magnitude of our mission. Share The TAP program is a transformative FDA initiative designed to accelerate the development and patient access to high-impact medical technologies. Entry into the program provides BiVACOR with proactive, strategic engagement with the FDA throughout the entire product life cycle, from development to commercialization, supporting more efficient, risk-informed decision-making. TAP participation is reserved for breakthrough-designated devices with the potential to significantly improve patient outcomes for serious or life-threatening conditions. 'Acceptance into the TAP program marks a major milestone not just for BiVACOR, but for the field of mechanical circulatory support as a whole,' said Daniel Timms, Founder and Chief Technology Officer of BiVACOR. 'The BiVACOR TAH has the potential to fundamentally redefine the standard of care for patients with end-stage heart failure. TAP access gives us a powerful framework for working hand-in-hand with the FDA to bring this technology to the patients who need it most.' The BiVACOR TAH is intended for use as a bridge to transplant in adults with severe, irreversible biventricular or univentricular heart failure, particularly for patients who cannot be treated with traditional left ventricular assist devices (LVADs). The system employs a magnetically levitated centrifugal pump, inspired by space and industrial technologies, which provides continuous, pulsatile, and physiologically responsive cardiac support. The FDA's acceptance letter to BiVACOR emphasized that the TAP program's inclusion reflects the agency's confidence in the technology's potential to transform clinical practice. As part of the program, BiVACOR will receive more regulatory guidance, earlier identification of scientific and evidentiary gaps, and greater coordination among stakeholders, including payers and patient advocacy groups. 'This isn't just a vote of confidence in BiVACOR, it's a vote of confidence in the future of heart replacement technology,' said William Cohn, MD, BiVACOR Chief Medical Officer and renowned cardiac surgeon. 'The TAP program gives us the opportunity to collaborate with the FDA at a level that aligns with the urgency and magnitude of our mission to bring a durable, fully implantable artificial heart to patients with no other options.' The TAP program was established as part of the FDA's efforts to modernize device development oversight and ensure the U.S. remains at the forefront of medical innovation. The program currently operates as a pilot under the Center for Devices and Radiological Health (CDRH), with acceptance based on strict criteria outlined in the Federal Register (87 FR 61605). BiVACOR's participation in TAP follows several recent milestones for the company, including its first-in-human implant as a bridge to support a patient awaiting a cardiac transplant. The company is now progressing toward expanded clinical trials in the U.S. and internationally. For more information on the FDA's TAP program, visit: Participation in the FDA's Total Product Life Cycle Advisory Program (TAP) does not imply FDA approval, clearance, or authorization. Inclusion in the TAP Pilot does not guarantee future marketing authorization or a regulatory outcome. The BiVACOR TAH is currently used as an investigational device and is not approved for commercial use. About BiVACOR BiVACOR ® is a clinical-stage medical device company developing a fully implantable, magnetically levitated Total Artificial Heart for long-term support of patients with end-stage biventricular heart failure. Founded by biomedical engineer Daniel Timms, PhD, and backed by leading experts in cardiovascular medicine including Dr. William E. Cohn and Dr. O.H. (Bud) Frazier, the company is conducting an FDA-approved Early Feasibility Study in the U.S. Headquartered in Huntington Beach, CA, with clinical operations in Houston and engineering offices in Gold Coast, Australia, BiVACOR is committed to addressing the global shortage of donor hearts through advanced, scalable technology. Learn more at
Business Upturn
44 minutes ago
- Business Upturn
Built with Now: Staffbase announces integration with ServiceNow to deliver seamless digital employee experience
NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) — Staffbase today announced a product integration with ServiceNow to unify digital workflows with internal communications, helping organizations extend the power of the ServiceNow AI Platform across the entire workforce. The joint effort enables Staffbase to create better experiences and drive value for customers by surfacing critical ServiceNow workflows in a way that is intuitive, accessible, and engaging for all employees, including frontline and non-desk workers. As a Build Partner, the certified Staffbase–ServiceNow integration provides embedded ServiceNow widgets and search functionality within the Staffbase platform and is available via the Staffbase website and the ServiceNow Store. Staffbase ensures that ServiceNow workflows are easily discoverable and usable for all employees through its mobile-first communications platform, solving a potential disconnect between digital systems and employee adoption. The result: higher ServiceNow adoption, faster task resolution, and greater ROI on digital investments. 'This integration reinforces our commitment to helping enterprises create a unified digital employee experience,' said David Maffei, Staffbase GM and SVP of the Americas. 'ServiceNow is the engine behind many critical workflows. Staffbase ensures those workflows reach every employee in a way that's intuitive, accessible, and actionable, especially for those outside of a traditional office setting.' 'Partnerships succeed best when we collaborate with a clear focus to drive successful customer outcomes,' said Michael Park, Senior Vice President, Global Partnerships and Channels at ServiceNow. 'Staffbase's integration with ServiceNow will empower customers to streamline workflows, enhance efficiency, and unlock new value on the ServiceNow AI Platform. I am thrilled to see the continued innovation we will achieve together to help organizations excel in today's dynamic business environment.' About Staffbase Staffbase is the leading employee communications cloud, equipping many of the world's leading companies with solutions to inspire every employee with motivating communication. With over 2000 customers, Staffbase helps organizations such as Adidas, Alaska Airlines, Audi, Blue Apron, DHL, and Whataburger to inspire their people to achieve great things together. Staffbase connects companies with their employees through a branded employee app, intranet, email, SMS, digital signage, and Microsoft 365 integrations, all of which can be managed through a single platform. Staffbase was named a leader in the 2024 Gartner® Magic Quadrant™ for Intranet Packaged Solutions. Staffbase is headquartered in Chemnitz, Germany and New York City. Please visit for more information. ServiceNow, the ServiceNow logo, Now, Now Platform, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Media contactMelanie BochmannSenior Director of Communications [email protected]
Yahoo
an hour ago
- Yahoo
Elastic Announces Elastic AI SOC Engine for Exposing Complex, Hidden Threats
Elastic AI SOC Engine (EASE) reduces alert fatigue and investigation time by integrating context-aware AI with existing SIEM and EDR tools SAN FRANCISCO, August 06, 2025--(BUSINESS WIRE)--Elastic (NYSE: ESTC), the Search AI Company, today announced the launch of Elastic AI SOC Engine (EASE), a new serverless, easy-to-deploy security package that brings AI-driven context-aware detection and triage into existing SIEM and EDR tools, without the need for an immediate migration or replacement. EASE delivers agentless integrations, AI-driven alert correlation using Elastic's Attack Discovery, and an AI Assistant that empowers SOC analysts to uncover hidden, coordinated threats faster and reduce manual investigation time. Delivered on the Elastic Cloud, EASE gives security teams a friction-reducing path to prioritize threats, reduce alert fatigue, and enhance the value of their current security investments. "SOC analysts are overwhelmed by high alert volumes and lack the AI support they need from their existing SIEM and EDR solutions to investigate threats effectively," said Santosh Krishnan, general manager, Observability & Security at Elastic. "EASE brings Elastic's proven AI capabilities into the security tools teams already use, to automatically prioritize threats, correlate alerts, and accelerate investigations, reducing the load on teams. When ready, teams can seamlessly migrate to Elastic Security for a unified, AI-driven platform that brings together SIEM, XDR, and cloud security, without missing a beat." EASE is designed for fast deployment and immediate value in security environments that rely on Splunk, Microsoft Sentinel, CrowdStrike, and other tools. EASE includes: Agentless integrations: Native, agentless alert ingest from third-party SIEM and EDR platforms that allow users to apply AI analysis to alerts immediately. AI-powered alert correlation: Users get access to Elastic Attack Discovery, which triages, correlates and prioritizes alerts, as well as a streamlined AI-powered alert view, which supports analysts with AI-powered summaries and context. Context-aware AI Assistant: Agentless data connectors enrich investigations with internal knowledge from sources including Jira, GitHub, and SharePoint, and support natural language queries and RAG-based search across organizational data. Transparent AI with model flexibility: Choose the LLM that works best for your organization, either your own, or the Elastic Managed LLM. AI Assistant responses are cited, so you know what data was used. All queries, responses, and token usage are fully logged and trackable. Operational dashboards: Out-of-the-box metrics highlight time savings, detection improvements, and ROI to help security teams demonstrate business value. "Elastic is tackling a common challenge: how to bring open and transparent AI into the SOC without starting from scratch, said Michelle Abraham, senior research director, Security and Trust, IDC. "EASE helps teams with faster detection and investigation using the tools they already have." To learn more about EASE, read the Elastic blog. To get started, start your free trial today. About Elastic Elastic (NYSE: ESTC), the Search AI Company, integrates its deep expertise in search technology with artificial intelligence to help everyone transform all of their data into answers, actions, and outcomes. Elastic's Search AI Platform — the foundation for its search, observability, and security solutions — is used by thousands of companies, including more than 50% of the Fortune 500. Learn more at Elastic and associated marks are trademarks or registered trademarks of Elasticsearch BV and its subsidiaries. All other company and product names may be trademarks of their respective owners. View source version on Contacts Media Contact Elastic PRPR-team@
